NR-607 DIAGNOSIS & MANAGEMENT IN PSYCHIATRIC-MENTAL
HEALTH ACROSS THE LIFESPAN III QUESTIONS AND CORRECT
ANSWERS (VERIFIED ANSWERS) PLUS RATIONALES 2026 Q&A |
INSTANT DOWNLOAD PDF.
Core Domains
Advanced Psychopharmacology and Treatment-Resistant
Conditions
Complex Diagnostic Reasoning and Differential Diagnosis
Psychotherapy Integration and Advanced Modalities
Severe and Persistent Mental Illness Across the Lifespan
Crisis Intervention, Risk Assessment, and Safety Planning
Neurobiology, Genetics, and Psychopathology
Ethical, Legal, and Professional Practice Issues
Cultural, Social, and Health Equity Considerations
Introduction
This comprehensive assessment evaluates the advanced knowledge
and clinical judgment required of the psychiatric-mental health
nurse practitioner in the third course of the diagnosis and
management sequence. It covers complex psychopharmacology,
treatment-resistant conditions, advanced diagnostic reasoning,
psychotherapy integration, and the management of severe and
persistent mental illness across the lifespan. Questions are multiple-
choice and scenario-based, emphasizing real-world application,
prioritization, and evidence-informed decision-making. The
examination is designed to reflect graduate-level PMHNP course
expectations and to strengthen readiness for safe, ethical, and
culturally responsive advanced psychiatric practice.
SECTION ONE: QUESTIONS 1-100
,1. A 42-year-old patient with treatment-resistant major depressive
disorder has failed adequate trials of sertraline, venlafaxine, and
bupropion. The PMHNP is considering augmentation. Which
agent has the strongest evidence for augmentation of
antidepressants in treatment-resistant depression?
A. 🟢 Aripiprazole
B. Lamotrigine
C. Buspirone
D. Mirtazapine
🔴 RATIONALE: Aripiprazole is FDA-approved as an adjunctive
treatment for major depressive disorder and has the strongest
evidence base for augmentation in treatment-resistant depression
among the options listed.
2. A patient with bipolar I disorder has had three mood episodes
in the past year despite adherence to lithium. The PMHNP
should consider switching to which agent with proven long-
term efficacy?
A. 🟢 Lamotrigine
B. Quetiapine
C. Valproate
D. Carbamazepine
🔴 RATIONALE: Quetiapine has the strongest evidence for long-
term prevention of both manic and depressive episodes in bipolar
I disorder. Lamotrigine is more effective for preventing depressive
episodes.
3. A patient with schizophrenia has not responded to adequate
trials of risperidone and olanzapine. Clozapine is initiated.
Which monitoring parameter is most critical during the first 18
weeks of therapy?
,A. Serum glucose
B. 🟢 Absolute neutrophil count
C. Liver function tests
D. Serum prolactin
🔴 RATIONALE: Clozapine carries the highest risk of
agranulocytosis, and weekly ANC monitoring is required for the
first 6 months, then biweekly for 6 months, and monthly
thereafter.
4. A patient with borderline personality disorder has completed a
course of dialectical behavior therapy but continues to struggle
with emotional dysregulation. Which adjunctive therapy has the
strongest evidence for reducing self-harm?
A. 🟢 Mentalization-based therapy
B. Cognitive behavioral therapy
C. Psychodynamic psychotherapy
D. Supportive therapy
🔴 RATIONALE: Mentalization-based therapy has strong evidence
for reducing self-harm and improving emotional regulation in
borderline personality disorder, particularly when DBT has been
insufficient.
5. A 16-year-old patient with severe OCD has failed trials of
fluoxetine and sertraline. Which medication has the strongest
evidence for treatment-resistant pediatric OCD?
A. Clomipramine
B. 🟢 Clomipramine
C. Risperidone
D. Atomoxetine
, 🔴 RATIONALE: Clomipramine, a tricyclic antidepressant, has
strong evidence for treatment-resistant OCD in pediatric patients
and is FDA-approved for OCD in children 10 years and older.
6. A patient with major depressive disorder and comorbid alcohol
use disorder is being treated with naltrexone. The patient asks
about the mechanism of action. The PMHNP explains that
naltrexone:
A. 🟢 Blocks opioid receptors, reducing alcohol cravings and
reward
B. Increases GABA activity to reduce anxiety
C. Inhibits serotonin reuptake
D. Blocks dopamine receptors
🔴 RATIONALE: Naltrexone is an opioid receptor antagonist that
reduces the rewarding effects of alcohol and decreases cravings
by blocking endogenous opioid activity.
7. A patient with PTSD and severe dissociative symptoms is being
evaluated for treatment. Which therapy is specifically designed
for PTSD with dissociation?
A. Prolonged exposure
B. 🟢 Phase-based trauma therapy
C. Cognitive processing therapy
D. Stress inoculation training
🔴 RATIONALE: Phase-based trauma therapy (such as the Tri-
Phasic Model) is specifically designed for PTSD with dissociation,
addressing stabilization, trauma processing, and integration in
distinct phases.
8. A patient with schizophrenia is started on clozapine. The
patient experiences a seizure during the titration phase. What is
HEALTH ACROSS THE LIFESPAN III QUESTIONS AND CORRECT
ANSWERS (VERIFIED ANSWERS) PLUS RATIONALES 2026 Q&A |
INSTANT DOWNLOAD PDF.
Core Domains
Advanced Psychopharmacology and Treatment-Resistant
Conditions
Complex Diagnostic Reasoning and Differential Diagnosis
Psychotherapy Integration and Advanced Modalities
Severe and Persistent Mental Illness Across the Lifespan
Crisis Intervention, Risk Assessment, and Safety Planning
Neurobiology, Genetics, and Psychopathology
Ethical, Legal, and Professional Practice Issues
Cultural, Social, and Health Equity Considerations
Introduction
This comprehensive assessment evaluates the advanced knowledge
and clinical judgment required of the psychiatric-mental health
nurse practitioner in the third course of the diagnosis and
management sequence. It covers complex psychopharmacology,
treatment-resistant conditions, advanced diagnostic reasoning,
psychotherapy integration, and the management of severe and
persistent mental illness across the lifespan. Questions are multiple-
choice and scenario-based, emphasizing real-world application,
prioritization, and evidence-informed decision-making. The
examination is designed to reflect graduate-level PMHNP course
expectations and to strengthen readiness for safe, ethical, and
culturally responsive advanced psychiatric practice.
SECTION ONE: QUESTIONS 1-100
,1. A 42-year-old patient with treatment-resistant major depressive
disorder has failed adequate trials of sertraline, venlafaxine, and
bupropion. The PMHNP is considering augmentation. Which
agent has the strongest evidence for augmentation of
antidepressants in treatment-resistant depression?
A. 🟢 Aripiprazole
B. Lamotrigine
C. Buspirone
D. Mirtazapine
🔴 RATIONALE: Aripiprazole is FDA-approved as an adjunctive
treatment for major depressive disorder and has the strongest
evidence base for augmentation in treatment-resistant depression
among the options listed.
2. A patient with bipolar I disorder has had three mood episodes
in the past year despite adherence to lithium. The PMHNP
should consider switching to which agent with proven long-
term efficacy?
A. 🟢 Lamotrigine
B. Quetiapine
C. Valproate
D. Carbamazepine
🔴 RATIONALE: Quetiapine has the strongest evidence for long-
term prevention of both manic and depressive episodes in bipolar
I disorder. Lamotrigine is more effective for preventing depressive
episodes.
3. A patient with schizophrenia has not responded to adequate
trials of risperidone and olanzapine. Clozapine is initiated.
Which monitoring parameter is most critical during the first 18
weeks of therapy?
,A. Serum glucose
B. 🟢 Absolute neutrophil count
C. Liver function tests
D. Serum prolactin
🔴 RATIONALE: Clozapine carries the highest risk of
agranulocytosis, and weekly ANC monitoring is required for the
first 6 months, then biweekly for 6 months, and monthly
thereafter.
4. A patient with borderline personality disorder has completed a
course of dialectical behavior therapy but continues to struggle
with emotional dysregulation. Which adjunctive therapy has the
strongest evidence for reducing self-harm?
A. 🟢 Mentalization-based therapy
B. Cognitive behavioral therapy
C. Psychodynamic psychotherapy
D. Supportive therapy
🔴 RATIONALE: Mentalization-based therapy has strong evidence
for reducing self-harm and improving emotional regulation in
borderline personality disorder, particularly when DBT has been
insufficient.
5. A 16-year-old patient with severe OCD has failed trials of
fluoxetine and sertraline. Which medication has the strongest
evidence for treatment-resistant pediatric OCD?
A. Clomipramine
B. 🟢 Clomipramine
C. Risperidone
D. Atomoxetine
, 🔴 RATIONALE: Clomipramine, a tricyclic antidepressant, has
strong evidence for treatment-resistant OCD in pediatric patients
and is FDA-approved for OCD in children 10 years and older.
6. A patient with major depressive disorder and comorbid alcohol
use disorder is being treated with naltrexone. The patient asks
about the mechanism of action. The PMHNP explains that
naltrexone:
A. 🟢 Blocks opioid receptors, reducing alcohol cravings and
reward
B. Increases GABA activity to reduce anxiety
C. Inhibits serotonin reuptake
D. Blocks dopamine receptors
🔴 RATIONALE: Naltrexone is an opioid receptor antagonist that
reduces the rewarding effects of alcohol and decreases cravings
by blocking endogenous opioid activity.
7. A patient with PTSD and severe dissociative symptoms is being
evaluated for treatment. Which therapy is specifically designed
for PTSD with dissociation?
A. Prolonged exposure
B. 🟢 Phase-based trauma therapy
C. Cognitive processing therapy
D. Stress inoculation training
🔴 RATIONALE: Phase-based trauma therapy (such as the Tri-
Phasic Model) is specifically designed for PTSD with dissociation,
addressing stabilization, trauma processing, and integration in
distinct phases.
8. A patient with schizophrenia is started on clozapine. The
patient experiences a seizure during the titration phase. What is
